The application of nanosponges to cancer drug delivery

Expert Opinion on Drug Delivery

Volumn 11, Issue 6, 2014, Pages 931-941

  Trotta, Francesco ^a   Dianzani, Chiara ^a   Caldera, Fabrizio ^a   Mognetti, Barbara ^a   Cavalli, Roberta ^a  

^a UNIVERSITY OF TURIN   (Italy)

Author keywords

Anticancer drugs; Cyclodextrins; Nanosponges; Prolonged release

Indexed keywords

ANTINEOPLASTIC AGENT; BETA CYCLODEXTRIN; DOXORUBICIN; FLUOROURACIL; NANOCARRIER; NANOSPONGE; PACLITAXEL; TAMOXIFEN; UNCLASSIFIED DRUG;

CANCER THERAPY; DRUG DELIVERY SYSTEM; IN VITRO STUDY; IN VIVO STUDY; NANOTECHNOLOGY; REVIEW;

ANTICANCER DRUGS; CYCLODEXTRINS; NANOSPONGES; PROLONGED RELEASE;

ANIMALS; ANTINEOPLASTIC AGENTS; CHEMISTRY, PHARMACEUTICAL; CYCLODEXTRINS; DELAYED-ACTION PREPARATIONS; DRUG CARRIERS; DRUG DELIVERY SYSTEMS; HUMANS; NANOPARTICLES;

EID: 84901263011     PISSN: 17425247     EISSN: 17447593     Source Type: Journal    
DOI: 10.1517/17425247.2014.911729     Document Type: Review

References (94)

1. Riehemann K, Schneider SW, Lunger TA, et al. Nanomedicine: Challenges and perspectives. Ang Chemie 2009;48:872-97
2. Sagnella SM, Gong X, Moghaddam MJ, et al. Nanostructured nanoparticles of self-Assembled lipid pro-drugs as a route to improved chemotherapeutic agents. Nanoscale 2011;3:919-24
3. Ali I, Rahis-Uddin, Salim K, et al. Advances in nano drugs for cancer chemotherapy. Curr Cancer Drug Targets 2011;11:135-46
4. Couvreur P. Nanoparticles in Drug delivery: Past, present and future. Adn Drug Deliv Rev 2013;65:21-3
5. Couvreur P, Roland A, Trouet A, et al. Nanocapsules: A new type of lysosomotropic carrier. FEBS Lett 1977;84:323-6 (Pubitemid 8246984
6. Chen Z. Small-molecule delivery by nanoparticles for anticancer therapy. Trends Mol Med 2010;16:594-602
7. Matsumura Y, Maeda H. A new concept for macromolecular therapeutics in cancer chemotherapy: Mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. Cancer Res 1986;46:6387-92 (Pubitemid 17221789
8. Lammers T, Kiessling F, Hennink WE, et al. Drug targeting to tumours: Principles, pitfalls and (pre-) clinical progress. J Control Release 2012;161:175-87
9. Maeda H, Wu J, Sawa T, et al. Tumor vascular permeability and the EPR effect in macromolecular therapeutics: A review. J Control Release 2000;65:271-84 (Pubitemid 30122932
10. Maeda H, Nakamura H, Fang J. The EPR effect for macromolecular drug delivery to solid tumors: Improvement of tumor uptake, lowering of systemic toxicity, and distinct tumor imaging in vivo. Adn Drug Deliv Rev 2013;65:71-9
11. Skinner SA, Tutton PJ, O'Brien PE. Microvascular architecture of experimental cotumors in the rat. Cancer Res 1990;50:2411-17 (Pubitemid 20134503
12. Decuzzi P, Godin B, Tanaka T, et al. Size and shape effects in the biodistribution of intravascularly injected particles. Control Release 2010;141:320-7
13. Wang MD, Shin DM, Jonathan W, et al. Nanotechnology for targeted cancer therapy. Expert Rev Anticancer Ther 2007;7:833-7 (Pubitemid 47007989
14. Arima H, Yamashita S, Mori Y, et al. In vitro and in vivo gene delivery mediated by lactosylated dendrimer/ alphacyclodextrin conjugates (G2) into hepatocytes. J Control Release 2010;146:106-17
15. Jeong SY, Park SJ, Yoon SM, et al. Systemic delivery and preclinical evaluation of Au nanoparticle containing b-lapachone for radiosensitization. J Control Release 2009;139:239-45
16. Ferrari M. Cancer nanotechnology: Opportunity and challenges. Nat Rev Cancer 2005;5:161-71
17. Liu Z, Tabakman S, Welsher K, et al. Carbon nanotubes in biology and medicine: In vitro and in vivo detection imaging and drug delivery. Nano Res 2009;2:85-120
18. Allen TM, Cullis P. Liposomal drug delivery systems: From concept to clinical applications. Adn Drug delivery 2013;65:36-48
19. Wang M, Thanou M. Targeting nanoparticles to cancer. Pharmacol Res 2010;62:90-9
20. Gabizon AA. Pegylated liposomal doxorubicin: Metamorphosis of an old drug into a new form of chemotherapy. Cancer Invest 2001;19:424-36 (Pubitemid 32525189
21. Desai N, Trieu V, Yao Z, et al. Increased antitumor activity, intratumor paclitaxel concentrations, and endothelial cell transport of cremophor-free, albumin-bound paclitaxel, ABI-007, compared with cremophor-based paclitaxel. Clin Cancer Res 2006;12:1317-24 (Pubitemid 43342524
22. Lee CL, Wu CC, Chiou H, et al. Mesopourous platinum nanosponges as electrocatalysis for the oxygen reduction reaction in an acidic electrolyte. Int J Hydrogen Energy 2011;36(11):6433-40
23. Trotta F, Tumiatti W. Cross-linked polymers based on cyclodextrins for removing polluting agents. WO03/085002 A1; 2003
24. Swaminathan S, Vavia PR, Trotta F, et al. Structural evidence of differential forms of nanosponges of betacyclodextrin and its effect on solubilization of a model drug. J Incl Phenom Macrocycl Chem 2013;76:201-11
25. Trotta F, Zanetti M, Cavalli R. Cyclodextrin-based nanosponges as drug carriers. Beilstein J Org Chem 2012;8:2091-9
26. Szejtl J. Introduction and general overview of cyclodextrin chemistry. Chem Rev 1998;98:1743-54
27. Martin Del Valle EM. Cyclodextrins and their uses: A review. Process Biochem 2004;39:1033-46
28. Kurkov SV, Loftsson T. Cyclodextrins. Int J Pharm 2013;453:167-80
29. Duchêne D, Ponchel G, Wouessidjewe D. Cyclodextrins in targeting. Application to nanoparticles. Adn Drug Deliv Rev 1999;36:29-40
30. Cavalli R, Trotta F, Trotta M, et al. Effect of alkylcarbonate of gammacyclodextrins with different chain lengths on Drug complexation and release characteristics. Int J Pharm 2007;339:197-204 (Pubitemid 46977608
31. Bilensoy E, Gurkaynak O, Lale Dogan AL, et al. Safety and efficacy of amphiphilic beta-cyclodextrin nanoparticles for paclitaxel delivery. Int J Pharm 2008;347:153-70
32. Cavalli R, Trotta F, Carlotti ME, et al. Nanoparticles derived from amphiphilic gamma-cyclodextrins. J Incl Phenom Macrocycl Chem 2007;57:657-61
33. Bencini M, Ranucci E, Ferruti P, et al. Poly (4-Acryloylmorpholine) oligomers carrying a beta-cyclodextrin residue at one terminus. J Polym Sci Part A Polym Chem 2008;46:1607-17 (Pubitemid 351310830
34. Vyas A, Saraf S, Saraf S. Cyclodextrin based novel drug delivery systems. J Incl Phenom Macrocycl Chem 2008;62:23-42
35. Binello A, Robaldo B, Barge A, et al. G Synthesis of cyclodextrin-based polymers and their use as debittering agents. J Appl Polym Sci 2008;107:2549-57 (Pubitemid 351204678
36. Cavalli R, Donalisio M, Civra A, et al. Enhanced antiviral activity of acyclovir loaded into beta-cyclodextrin-poly(4-Acryloylmorpholine)conjugate nanoparticles. J Control Release 2009;137:116-22
37. Moya-Ortega MD, Alvarez-Lorenzo C, Concheiro A, et al. Cyclodextrin-based nanogel for pharmaceutical applications. Int J Pharm 2012;428:152-63
38. Li D, Ma M. Cyclodextrin polymer separation materials. WO9822197; 1998
39. Trotta F, Cavalli R, Tumiatti et al. Ultrasound assisted synthesis of cyclodextrin based nanosponges. WO0002814A1; 2006
40. Trotta F, Cavalli R. Characterization and applications of new hyper-cross-linked Cyclodextrins. Compos Interfaces 2009;16:39-48
41. Rossi B, Caponi S, Castiglione F, et al. Networking properties of cyclodextrinbased cross-linked polymers probed by inelastic light-scattering experiments. J Phys Chem B 2012;116:5323-7
42. Cavalli R, Trotta F, Tumiatti W. Cyclodextrin-based nanosponges for drug delivery. J Inclus Phenom Macroccycl Chem 2006;56:209-13
43. Rao M, Bajaj A, Khole I, et al. In vitro and in vivo evaluation of beta-cyclodextrin-based nanosponges of telmisartan. J Inclus Phenom Macroccycl Chem 2013;77:135-45
44. Shende P, Trotta F, Gaud RS, et al. Influence of different techniques on formulation and comparative characterization of inclusion complexes of ASA with beta-cyclodextrin and inclusion complexes of ASA with PMDA crosslinked beta-cyclodextrin nanosponges. J Incl Phenom Macrocycl Chem 2012;74:447-54
45. Berto S, Bruzzoniti MC, Cavalli R, et al. Synthesis of new ionic beta-cyclodextrin polymers and characterisation of their heavy metals retention. J Incl Phenom Macrocycl Chem 2007;57:631-6
46. Swaminathan S, Cavalli R, Trotta F, et al. In vitro release modulation and conformational stabilization of a model protein using swellable polyamidoamine nanosponges of beta-cyclodextrin. J Incl Phenom Macrocycl Chem 2010;68:183-91
47. Swaminathan S, Vavia PR, Trotta F, et al. Nanosponges encapsulating dexamethasone for ocular delivery: Formulation Design, physicochemical characterization, safety and corneal permeability assessment. J Biomed Nanotech 2013;9:998-1007
48. Cavalli R, Akhter AK, Bisazza A, et al. Vavia, Nanosponge formulations as oxygen Delivery systems. Int J Pharm 2010;402:254-7
49. Seglie L, Martina K, Devecchi M, et al. The effects of 1-MCP in cyclodextrinbased nanosponges to improve the vase life of Dianthus caryophyllus cut flowers. Postharvest Biol Technol 2011;59:200-5
50. Lembo D, Swaminathan S, Donalisio M, et al. Encapsulation of Acyclovir in new carboxylated cyclodextrin-based nanosponges improves the agent's antiviral efficacy. Int J Pharm 2013;443:262-72
51. Swaminathan S, Vavia P R, Trotta F, et al. Itraconazole in nanosponges. Incl Phenom Macrocycl Chem 2007;57:89-94
52. Malingre MM, Beijnen JH, Schellens JH. Oral delivery of taxanes. Invest New Drugs 2001;19:155-62 (Pubitemid 32423720
53. Gelderblom H, Verweij J, Nooter K, et al. The drawbacks and advantages of vehicle selection for drug formulation. Eur J Cancer 2001;37:1590-8 (Pubitemid 32778603
54. Goldspiel BR. Paclitaxel compatibility with ethylene vinyl acetate bags. Ann Pharmacother 1999;33:873-4 (Pubitemid 29387673
55. Agueros M, Ruiz-Gaton L, Vauthier C, et al. Combined hydroxypropyl-beta- cyclodextrin and poly (anhydride) nanoparticles improve the oral permeability of paclitaxel. Eur J Pharm Sci 2009;38:405-13
56. Veltkamp SA, Thijssen B, Garrigue JS, et al. A novel self- microemulsifying formulation of paclitaxel for oral administration to patients with advanced cancer. Br J Cancer 2006;95:729-34 (Pubitemid 44373489
57. Mu L, Feng SS. A novel controlled release formulation for the anticancer drug paclitaxel (Taxol): PLGA nanoparticles containing vitamin E TPGS. J Control Release 2003;86:33-48 (Pubitemid 35469120
58. Cavalli R, Caputo O, Gasco MR. Preparation and characterization of solid lipid nanospheres containing paclitaxel. Eur J Pharm Sci 2000;10:305-9 (Pubitemid 30317466
59. Peltier S, Oger JM, Lagarce F, et al. Enhanced oral paclitaxel bioavailability after administration of paclitaxel-loaded lipid nanocapsules. Pharm Res 2006;23:1243-50 (Pubitemid 43946146
60. Lundberg BB. Preparation and characterization of polymeric pH-sensitive STEALTH- nanoparticles for tumor delivery of a lipophilic prodrug of paclitaxel. Int J Pharm 2011;408:208-12
61. Hamada H, Ishiharaa K, Masuokaa N, et al. Enhancement of water-solubility and bioactivity of paclitaxel using modified cyclodextrins. J Biosci Bioeng 2006;102(4):369-71 (Pubitemid 44781320
62. Park K. Efficient oral delivery of paclitaxel using cyclodextrin complexes. J Control Release 2010;145(1):1
63. Mognetti B, Barberis A, Marino S, et al. In vitro enhancement of anticancer activity of paclitaxel by a Cremophor free cyclodextrin-based nanosponge formulation. J Incl Phenom Macrocycl Chem 2012;74:201-10
64. Ansari KA, Torne SI, Vavia PR, et al. Paclitaxel loaded nanosponges: In vivo characterization and cytotoxycity study on MCF-7 cell line culture. Curr Drug Deliv 2011;8:192-202
65. Torne S, Ansari K, Vavia P, et al. Enhanced oral paclitaxel bioavailability after administration of paclitaxel-loaded nanosponges. Drug Deliv 2010;17:419-25
66. Heel RC, Brogden RN, Speight TM, et al. Tamoxifen: A review of its pharmacological properties and therapeutic use in the treatment of breast cancer. Drugs 1978;16:1-24 (Pubitemid 8365347
67. Torne S, Darandale S, Vavia P, et al. Cyclodextrin-based nanosponges: Effective nanocarrier for Tamoxifen Delivery. Pharm Dev Technol 2013;18:619-25
68. Hatefi A, Amsden B. Camptothecin Delivery methods. Pharm Res 2002;19:1389-99 (Pubitemid 35266542
69. Mina KH, Parka K, Kimc YS, et al. Hydrophobically modified glycol chitosan nanoparticles-encapsulated camptothecin enhance the drug stability and tumor targeting in cancer therapy. J Control Release 2008;127(3):208-18
70. Luo X, Jia G, Song H, et al Promoting antitumor activities of hydroxycamptothecin by encapsulation into acid-labile nanoparticles using electrospraying. Research 2014;31(1):46-59
71. Davis ME. Design and development of IT-101, a cyclodextrin-containing polymer conjugate of camptothecin. Adn Drug Deliv Rev 2009;61:1189-92
72. Swaminathan S, Pastero L, Serpe L, et al. Cyclodextrin-based nanosponges encapsulating camptothecin: Physicochemical characterization, stability and cytotoxicity. Eur J Pharm Biopharm 2010;74:193-201
73. Minelli R, Cavalli R, Ellis L, et al. Nanosponge-encapsulated camptothecin exerts anti-Tumor activity in human prostate cancer cells. Eur J Pharm Sci 2012;47:686-94
74. Trotta F, Zanetti M, Cavalli R. Cyclodextrin-based nanosponges as drug carriers. Beilstein J Org Chem 2012;8:2091-9
75. Available from: https://www.doxil.com/
76. Cavalli R, Trotta F, Tumiatti WJ. Cyclodextrin-based nanosponges for drug delivery. J Incl Phenom Macrocycl Chem 2006;56:209-13
77. Darandale SS, Vavia PR. Cyclodextrin based nanosponges of curcumin: Formulation and physicochemical characterization. J Incl Phenom Macrocycl Chem 2013;75:315-22
78. Naksuriyaa O, Okonogia S, Raymond M, et al. Curcumin nanoformulations: A review of pharmaceutical properties and preclinical studies and clinical data related to cancer treatment. Biomaterials 2014;35:3365-83
79. Tønnesen HH, Másson M, Loftsson T. Studies of curcumin and curcuminoids. XXVII. Cyclodextrin complexation: Solubility, chemical and photochemical stability. Int J Pharm 2002;244:127-35 (Pubitemid 35245453
80. Kristin N, Baglole PG, Boland BD, et al. Chemistry, fluorescence enhancement of curcumin upon inclusion into parent and modified cyclodextrins. J Photochem Photobio A 2005;173(3):230-7
81. Amri A, Chaumeil JC, Sfar S, Charrueau C. Administration of resveratrol: What formulation solutions to bioavailability limitations?. J Control Release 2012;158:182-93
82. Lu Z, Chen R, Fu R, et al. Cytotoxicity and inhibition of lipid peroxidation activity of resveratrol/cyclodextrin inclusion complexes. J Incl Phenom Macrocycl Chem 2012;73:313-20
83. Sapino S, Carlotti ME, Caron G, et al. In silico design, photostability and biological properties of the complex resveratrol/hydroxypropylbeta- cyclodextrin. J Incl Phenom Macrocycl Chem 2009;63:171-80
84. Berta G, Sapino S, Carlotti et al. Chemoprevention of 7,12-dimethylbenz [a]anthracene (DMBA)-induced oral carcinogenesis in hamster cheek pouch by topical application of resveratrol complexed with 2-hydroxypropylgamma- cyclodextrin. Oral Oncol 2010;46:42-8
85. Ansari KA, Vavia PR, Trotta F, et al. Cyclodextrin-based nanosponges for delivery of resveratrol: In vitro characterisation, stability, cytotoxicity and permeation study. AAPS Pharm Sci Tech 2011;12(1):279-86
86. Hoffman A. Stimuli-responsive polymers: Biomedical applications and challenges for clinical translation. Adn Drug Deliv Rev 2013;65:10-16
87. Cheng R, Feng F, Meng F, et al. Glutathione-responsive nano-vehicles as a promising platform for targeted intracellular drug and gene delivery. J Control Release 2011;152:2-12
88. Ejaz M, Yu H, Yan Y, et al. Evaluation of redox-responsive disulfide cross-linked poly(hydroxyethyl methacrylate) hydrogels. Polymer (Guildf) 2011;52:5262-70
89. Trotta F, Cavalli R. New Glutathione bio-responsive cyclodextrin nanosponges. 3rd European Cyclodextrin Congress; 3-6 October 2013; Antalya, Turkey
90. Cavalli R, Argenziano M, Dianzani C, et al. Disulfide nanosponges as innovative glutathione-responsive nanocarrier for doxorubicin Delivery. Submitted 41th CRS meeting; Chicago; July. 2014
91. Trotta F, Shende P, Biasizzo M. Method for preparing dextrin nanosponges; WO2012/147069 A1; 2012
92. Available from: Http://www. observatorynano.eu/project/filesystem/ files/HMN%20report.pdf
93. Trotta F. Ciclodextrin nanosponges and their applications. In: Bilensoy E, editor. Cyclodextrins in pharmaceutics, cosmetics and biomedicine. Hoboken; N.J.:Wiley: 2011. p. 323-42
94. Chilajwar SV. Cyclodextrin-based nanosponges: A propitious platform for enhancing drug delivery. Expert Opin Drug Deliv 2014;11:111-20